These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24871551)

  • 1. Investigation of dry powder inhaler (DPI) resistance and aerosol dispersion timing on emitted aerosol aerodynamic particle sizing by multistage cascade impactor when sampled volume is reduced from compendial value of 4 L.
    Mohammed H; Arp J; Chambers F; Copley M; Glaab V; Hammond M; Solomon D; Bradford K; Russell T; Sizer Y; Nichols SC; Roberts DL; Shelton C; Greguletz R; Mitchell JP
    AAPS PharmSciTech; 2014 Oct; 15(5):1126-37. PubMed ID: 24871551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen eight-stage cascade impactor (ACI).
    Mohammed H; Roberts DL; Copley M; Hammond M; Nichols SC; Mitchell JP
    AAPS PharmSciTech; 2012 Sep; 13(3):875-82. PubMed ID: 22678745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
    Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
    AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Internal Volumes of Pharmaceutical Compendial Induction Port, Next-Generation Impactor With and Without Its Pre-separator, and Several Configurations of the Andersen Cascade Impactor With and Without Pre-separator.
    Roberts DL; Chambers F; Copley M; Mitchell JP
    J Aerosol Med Pulm Drug Deliv; 2020 Aug; 33(4):214-229. PubMed ID: 32101074
    [No Abstract]   [Full Text] [Related]  

  • 5. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
    Mohan M; Lee S; Guo C; Peri SP; Doub WH
    AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI.
    Kamiya A; Sakagami M; Byron PR
    J Pharm Sci; 2009 Mar; 98(3):1028-39. PubMed ID: 18661538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.
    Shur J; Lee S; Adams W; Lionberger R; Tibbatts J; Price R
    AAPS J; 2012 Dec; 14(4):667-76. PubMed ID: 22723022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A counter-swirl design concept for dry powder inhalers.
    Chaugule V; Dos Reis LG; Fletcher DF; Young PM; Traini D; Soria J
    Int J Pharm; 2024 Jan; 650():123694. PubMed ID: 38081562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multi-laboratory in Vitro Study to Compare Data from Abbreviated and Pharmacopeial Impactor Measurements for Orally Inhaled Products: a Report of the European Aerosol Group (EPAG).
    Nichols SC; Mitchell JP; Sandell D; Andersson PU; Fischer M; Howald M; Pengilley R; Krüger P
    AAPS PharmSciTech; 2016 Dec; 17(6):1383-1392. PubMed ID: 26762338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
    Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
    AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: the influence of flow and volume.
    Yakubu SI; Assi KH; Chrystyn H
    Int J Pharm; 2013 Oct; 455(1-2):213-8. PubMed ID: 23892154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of Aerodynamic Particle Size Distribution of Orally Inhaled Products by Cascade Impactor: How to Let the Product Specification Drive the Quality Requirements of the Cascade Impactor.
    Roberts DL; Mitchell JP
    AAPS PharmSciTech; 2019 Jan; 20(2):57. PubMed ID: 30623259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.
    Farkas D; Hindle M; Longest PW
    J Aerosol Med Pulm Drug Deliv; 2018 Aug; 31(4):255-265. PubMed ID: 29261454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.
    Mitchell JP; Nagel MW; Avvakoumova V; MacKay H; Ali R
    AAPS PharmSciTech; 2009; 10(1):243-51. PubMed ID: 19280348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler.
    Bass K; Farkas D; Longest W
    AAPS PharmSciTech; 2019 Nov; 20(8):329. PubMed ID: 31676991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
    Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.
    Farkas D; Hindle M; Bonasera S; Bass K; Longest W
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):83-98. PubMed ID: 31464559
    [No Abstract]   [Full Text] [Related]  

  • 19. The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.
    Mitchell JP; Nagel MW; Avvakoumova V; MacKay H; Ali R
    AAPS PharmSciTech; 2009; 10(1):252-7. PubMed ID: 19291411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminating Ability of Abbreviated Impactor Measurement Approach (AIM) to Detect Changes in Mass Median Aerodynamic Diameter (MMAD) of an Albuterol/Salbutamol pMDI Aerosol.
    David Christopher J; Patel RB; Mitchell JP; Tougas TP; Goodey AP; Quiroz J; Andersson PU; Lyapustina S
    AAPS PharmSciTech; 2017 Nov; 18(8):3296-3306. PubMed ID: 28589305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.